Publications by authors named "J Tom Sims"

Diabetes Mellitus (DM) is a severe and chronic metabolic disorder characterized by hyperglycaemia and various complications, including cardiovascular disease. It is diagnosed when fasting plasma glucose (FPG) level is126 mg/dL (7.0 mmol/L) or higher [1].

View Article and Find Full Text PDF

Background: Time to deterioration (TTD) endpoints are often utilized in the analysis of patient-reported outcome (PRO) data in oncology clinical trials but different endpoint definitions and analysis frameworks exist that can impact result interpretation. This review examined the analysis, reporting and heterogeneity of TTD endpoints in the literature, the impact of analysis methods on results, and provides recommendations for future trials.

Methods: A targeted literature review of articles published between 2017 and 2022 was performed to collate TTD endpoints reported in oncology randomized controlled trials (RCTs).

View Article and Find Full Text PDF

Introduction: Middle meningeal artery embolization (MMAe) is increasingly utilized as a primary or secondary treatment for chronic subdural hematoma (cSDH) and is usually performed with liquid embolics or particles. Outcomes after MMAe with coiling as a standalone treatment, or an adjunct to other agents, have not been reviewed.

Methods: A systematic review of the literature was performed to identify all original research that included patients who underwent standalone or adjunctive coiling for MMAe.

View Article and Find Full Text PDF

Insufficient sleep (short sleep duration and poor sleep quality) is associated with obesity risk. Emerging adults (ages 18-28 years) have a greater risk of excess weight gain and insufficient sleep, and these risks are higher in Black individuals. Using a measurement burst design, we assessed associations between sleep with energy balance components and obesity marker changes over 6 months in 15 Black emerging adults (12 females; age 21±2.

View Article and Find Full Text PDF
Article Synopsis
  • MERS-CoV is a serious virus with a 36% death rate in humans, and there's currently no vaccine or treatment approved for use in humans or camels.
  • Researchers developed special miniproteins that effectively bind to and neutralize various forms of the MERS-CoV spike protein, which is crucial for the virus's ability to infect cells.
  • Testing in mice showed that administering one of these miniproteins intranasally can protect against MERS-CoV infection, suggesting potential for further clinical development as a new preventive measure against this virus.
View Article and Find Full Text PDF